Results 81 to 90 of about 149,546 (225)
The FASEB Journal, Volume 40, Issue 18, 30 September 2026.Chronic kidney disease (CKD) is characterized by persistent inflammation that drives progressive renal injury and fibrosis. In this study, we demonstrate that disulfiram markedly attenuates kidney injury and fibrosis in adenine‐induced nephropathy by suppressing innate immune responses and reducing DNA damage and cellular senescence.
Saori Kin +5 more
wiley +1 more source
Pregnancy in IgA nephropathy [PDF]
, 1991 Pregnancy in IgA nephropathy. The impacts of IgA nephropathy and pregnancy on each other were evaluated in 118 women who conceived 168 times between 1970 and 1988. Rates of spontaneous abortion, normal delivery, live birth and perinatal death Were 9, 66,
Abe, Shinichi
core +1 more source
Current status of clinical studies of IgA nephropathy with minimal proteinuria
Linchuang shenzangbing zazhi, 2020 Patients with IgA nephropathy with minimal proteinuria(proteinuria
SHI Yu-zhen +3 more
doaj
Treatment of Pediatric IgA Nephropathy [PDF]
, 2007 IgA nephropathy is the most common chronic glomerulopathy in children and young adults. Although most of the early studies on pediatric IgA nephropathy concluded that it was a benign condition, more recent data have shown that a significant proportion of
Butani, Lavjay +3 more
core +1 more source
Multi‐Omic Profiling Reveals Immune Cell Priming Signature Linked to Lupus Prognosis
Arthritis &Rheumatology, Volume 78, Issue 9, Page 1878-1891, September 2026.Objective Systemic lupus erythematosus (SLE) is a multiorgan disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith +23 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 9, September 2026.ABSTRACT Despite therapeutic advances, early mortality remains a significant challenge in multiple myeloma (MM) patients with renal impairment (RI), with no validated prognostic models currently available for this high‐risk subgroup. This multicenter, retrospective study aimed to develop and validate a practical nomogram for predicting early death ...
Menghan Liu +11 more
wiley +1 more source
IgA Polyspecific autoantibodies in IgA nephropathy
, 1990 SUMMARY The specificity of circulating and kidney-bound IgA during IgA nephropathy is suit a matter of discussion. In the present study, high levels of IgA antibodies directed against a panel of self and non-out of the seven kidney ...
H LOUZIR +5 more
core +1 more source
Journal of Cell Communication and Signaling, Volume 20, Issue 3, September 2026.Diagnostic value of BTG2 and its immunoregulatory mechanism in IgAN. This study reveals that BTG2 improves immune microenvironment dysregulation, attenuates inflammation, and reduces fibrosis by promoting the expansion of T follicular helper cells, inducing macrophage polarization toward an M2 anti‐inflammatory phenotype, and inhibiting the TGF‐β1 ...
Min Kou +4 more
wiley +1 more source
Introduction Immunoglobulin A (IgA) nephropathy is a common immune-mediated kidney disease leading to high blood pressure and may progress to kidney failure. None of the present treatments are disease-modifying or prolong life.
Doggrell, Sheila A
core +1 more source
Sparsentan in IgA nephropathy: a plain language summary of publication for the PROTECT study
Therapeutic Advances in Rare DiseaseSummary What is this summary about? Sparsentan (FILSPARI ® ) is a once-daily pill for people with Immunoglobulin A (IgA) nephropathy who are at high risk for worsening kidney disease.
Brad H. Rovin +3 more
doaj +1 more source